Biotech Watchlist: Top Stocks to Research Now
Biotech stole the midday tape while the rest of the market slid on hot CPI.
One small drugmaker jumped about 160% on trial data. Another hit its pivotal endpoint and still fell about 10%.
Here are 4 worth researching. 👇
📌 The Watchlist
1. PepGen | $PEPG: Develops oligonucleotide therapies for rare genetic diseases. Its DM1 drug showed 46.5% splicing correction in the 10 mg/kg cohort, the best result reported so far, and the safety board advanced the trial to the highest 12.5 mg/kg dose.
2. Beam Therapeutics | $BEAM: Builds base editing genetic medicines. Its sickle cell therapy risto-cel met its pivotal trial endpoint, 12 months free of severe pain crises, and Beam plans a BLA filing as early as year end 2026. Shares still fell about 10% midday.
3. Senseonics | $SENS: Makes long term implantable glucose monitors for people with diabetes. Q3 revenue hit a record $19.6M, up about 140% year over year, and it raised full year guidance to $68M to $70M for the third time. Shares rose about 30%.
4. Harrow | $HROW: Sells branded eye care drugs. Q3 revenue rose about 39% to a record $99.3M, led by VEVYE at $39.7M, up 75% year over year. Shares rose about 12% midday.
📌 The Part Worth Saving
A trial readout is a reason to research a stock. It is not a reason to buy blindly.
Look for:
- Data on enough patients to mean something, not a handful
- Cash to survive until the next readout
- A clear next step, like a filing date or a Phase 3 plan
- What the market already priced in before the news
The best question: When a stock falls on good news, is the market doubting the data or the price it already paid?
Education only, not financial advice.